Kite Pharma Names New R&D Head

Santa Monica-based biopharmaceuticals firm Kite Pharma, which is developing products for the treatment of cancer, said today that it has named David D. Chang, M.D., Ph.D., as its new Executive Vice President, Research and Development, and Chief Medical Officer. Chang was most recently at Amgen, serving as Vice President of Global Development and Head of Hematology-Oncology. Chang had been at Amgen since 2002, and previously had been associate professor of medicine and of microbiology, immunology and molecular genetics at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA).